NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
SOUTH SAN FRANCISCO, Calif., September 14, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),today announced updated data from the ongoing...
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
SOUTH SAN FRANCISCO, Calif., September 11, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research...
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif., August 22, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2...
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - - REFRαME-O1 Part 2 (randomized portion) of...
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
SOUTH SAN FRANCISCO, Calif., July 9, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman,...
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in...
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in follow up – SOUTH...
Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”
Bill Newell describes this week’s deal with Ipsen, the folate receptor alpha space, designing therapies with non-cell protein synthesis, and Sutro’s numerous partnerships Speakers: Bill Newell, CEO, Sutro Biopharma Bard Loncar, Founder, Biotech TV
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., April 2, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten...
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors
» Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development » STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target »...